Abstract
Current investigation aimed to evaluate a formulation of selenium nanoparticles (SeNPs) using Naringenin/Baicalin in streptozotocin-induced diabetic mice and INS-1 pancreatic β-cells. Nanoparticles were characterized using Fourier Transform-infrared, ultra-violet-visible, scanning electron microscopy, energy-dispersive X-ray spectroscopy, and Zetasizer showing the existence of
NAR/BAI on the surface of Se NPs. NAR/BAI/SeNPs have sizer ranging between 80 nm and 119 nm, showing a negative potential of -22.3 mV and a polydispersity index (PDI) of -0.249, indicating that they form a stable dispersion with stability within five months. The EE and LC flavonoids-loaded NPs were 80.1% and 25.4%, respectively. All parameter biochemical were altered by diabetic induction in mice; after 8 weeks of treatment, blood glucose, insulin levels, lipid profile, and glycosylated hemoglobin exhibited significant glucose and insulin effect in the oral glucose tolerance test, indicating improved insulin resistance. In the liver, NAR/BAI/SeNPs increase superoxide dismutase, Catalase glutathione peroxidase, as well as reduce lipid peroxidation, and transaminases aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase activities improved liver function elevating liver and muscle glycogen content, protects pancreatic b cells against high glucose-induced damage due to its synergistic effect between selenium with flavonoids. According to the results, NAR/BAI/SeNPs exhibit an anti-diabetic effect protecting and repairing pancreatic b cells.